Esketamine hydrochloride in the management of moderate-to-severe depressive symptoms in patients undergoing multiple wound repair surgeries: A multi-centre randomized, double-blind, placebo-controlled trial

Abstract

Introduction: Patients undergoing multiple wound repair surgeries often develop moderate-to-severe anxiety and depression. However, there is a lack of effective rapid emotional intervention strategies during the perioperative period.

Methods: This multi-centre, randomized, double-blind, placebo-controlled trial involved 130 adult patients (65 in the esketamine group and 65 in the placebo group). Participants were randomly assigned to receive either esketamine (0.2–0.3 mg/kg) or saline intravenously during surgery. The primary outcome was the response rate (proportion of patients with ≥50% reduction in MADRS total score from baseline) on postoperative days (PODs) 1–3, evaluated using the Montgomery–Åsberg depression rating scale (MADRS). The secondary outcome was the remission rate (proportion of patients with MADRS total score ≤10) on postoperative days (PODs) 1–3; scores on the Patient Health Questionnaire-9 (PHQ-9), the Hospital Anxiety and Depression Scale-Anxiety subscale (HADS-A); and esketamine-related neuropsychiatric adverse events assessed using the Young Mania Rating Scale (YMRS), Clinician-Administered Dissociative States Scale (CADSS), and Brief Psychiatric Rating Scale (BPRS) within 30 days after surgery.

Results: The esketamine group showed a significantly higher response rate than the placebo group on POD 1–3. (POD 1: 53.8% vs. 26.2%, p = 0.001; POD 2: 60.0% vs. 40.0%, p = 0.009; POD 3: 73.8% vs. 53.8%, p = 0.018). The esketamine group also showed a higher remission rate and lower MADRS scores (POD 1: 33.8% vs. 10.8%, p = 0.002; POD 2: 40.0% vs. 23.1%, p = 0.038; POD 3: 56.9% vs. 23.1%, p < 0.001). Esketamine improved HADS-A and PHQ-9 scores by POD 3 without increasing neuropsychiatric adverse events within 30 days postoperatively.

Conclusions: The results demonstrate that the intraoperative use of low-dose esketamine can rapidly and effectively alleviate moderate-to-severe anxiety and depressive symptoms in the early postoperative period (POD 1–3) among patients requiring repeated debridement surgeries without increasing neuropsychiatric or systemic adverse events within 30 days after surgery.

Keywords

esketamine / Montgomery-Åsberg depression rating scale / multiple trauma / postoperative complications / postoperative depression / Esketamine, Postoperative Depression, Multiple Trauma, Postoperative Complications, Montgomery-Asberg Depression Rating Scale

References

[1] Shoib S, Islam SMS, Arafat SY, Hakak SA. Depression and suicidal ideation among the geriatric population of Kashmir, India. Int J Soc Psychiatry. 2021; 67: 651-655.

[2] Klim SM, Amerstorfer F, McNally MA, et al. The sinus tract in bone and joint infection: minimally invasive salvation or prolonged suffering? A multicenter study. J Pers Med. 2023; 13: 737.

[3] Rodrigues KC, Toledo RA, Coutinho FL, et al. Assessment of depression, anxiety, quality of life, and coping in long-standing multiple endocrine neoplasia type 2 patients. Thyroid Off J Am Thyroid Assoc. 2017; 27: 693-706.

[4] Jovanovic K, Kalezic N, Sipetic Grujicic S, et al. Preoperative anxiety is associated with postoperative complications in vascular surgery: a cross-sectional study. World J Surg. 2022; 46: 1987-1996.

[5] Ghoneim MM, O'Hara MW. Depression and postoperative complications: an overview. BMC Surg. 2016; 16: 5.

[6] Pan X, Wang J, Lin Z, et al. Depression and anxiety are risk factors for postoperative pain-related symptoms and complications in patients undergoing primary total knee arthroplasty in the United States. J Arthroplasty. 2019; 34: 2337-2346.

[7] Rodrigues HF, Furuya RK, Dantas RAS, et al. Association of preoperative anxiety and depression symptoms with postoperative complications of cardiac surgeries. Rev Lat Am Enfermagem. 2018; 26:e3107.

[8] Etcheson JI, Gwam CU, George NE, et al. Patients with major depressive disorder experience increased perception of pain and opioid consumption following total joint arthroplasty. J Arthroplasty. 2018; 33: 997-1002.

[9] Martinazzi BJ, Monahan PF, Miltenberg B, et al. Preoperative acute depressive episodes are associated with increased medication prescribing and inpatient services after primary arthroscopic rotator cuff repair. Arthrosc J Arthrosc Relat Surg Off Publ Arthrosc Assoc N Am Int Arthrosc Assoc. 2025; 41: 2730-2737.e2.

[10] Strøm J, Bjerrum MB, Nielsen CV, et al. Anxiety and depression in spine surgery-a systematic integrative review. Spine J Off J North Am Spine Soc. 2018; 18: 1272-1285.

[11] Fu D-J, Ionescu DF, Li X, et al. Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I). J Clin Psychiatry. 2020; 81:19m13191.

[12] Canuso CM, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Focus Am Psychiatr Publ. 2019; 17: 55-65.

[13] Wen Y, Mao M, Jiang M, et al. Efficacy and safety of perioperative application of esketamine on postoperative depression: a meta-analysis of randomized controlled studies. Int J Surg Lond Engl. 2025; 111: 1191-1202.

[14] Lou X-J, Qiu D, Ren Z-Y, et al. Efficacy and safety of esketamine for perioperative depression in patients undergoing elective surgery: a meta-analysis of randomized controlled trials. Asian J Psychiatry. 2024; 95:103997.

[15] Qiu D, Wang X-M, Yang J-J, et al. Effect of intraoperative esketamine infusion on postoperative sleep disturbance after gynecological laparoscopy: a randomized clinical trial. JAMA Netw Open. 2022; 5:e2244514.

[16] Horowitz M, Moncrieff J. Esketamine: uncertain safety and efficacy data in depression. Br J Psychiatry J Ment Sci. 2021; 219: 621-622.

[17] Luo T, Deng Z, Ren Q, et al. Effects of esketamine on postoperative negative emotions and early cognitive disorders in patients undergoing non-cardiac thoracic surgery: a randomized controlled trial. J Clin Anesth. 2024; 95:111447.

[18] Wang H, Wang L, Gao J, Zhou F. Effect of intravenous esketamine on postoperative sleep disturbance, anxiety, and depression in elderly patients undergoing laparoscopic abdominal surgery: a randomized controlled trial. BMC Geriatr. 2025; 25: 148.

[19] Agha R, Mathew G, Rashid R, et al. Transparency in the reporting of artificial INtelligence—the TITAN guideline. Prem J Sci. 2025; 10:100082.

[20] Hopewell S, Chan A-W, Collins GS, et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ. 2025; 389:e081123.

[21] Bech P, Andersen HF, Wade A. Effective dose of escitalopram in moderate versus severe DSM-IV major depression. Pharmacopsychiatry. 2006; 39: 128-134.

[22] Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry J Ment Sci. 1979; 134: 382-389.

[23] Lener MS, Kadriu B, Zarate CA. Ketamine and beyond: investigations into the potential of glutamatergic agents to treat depression. Drugs. 2017; 77: 381-401.

[24] Hung K-C, Kao C-L, Ho C-N, et al. The impact of perioperative ketamine or esketamine on the subjective quality of recovery after surgery: a meta-analysis of randomised controlled trials. Br J Anaesth. 2024; 132: 1293-1303.

[25] Glue P, Loo C, Fam J, et al. Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial. Nat Med. 2024; 30: 2004-2009.

[26] Phillips JL, Norris S, Talbot J, et al. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2020; 45: 606-612.

[27] Castro M, Wilkinson ST, Al Jurdi RK, et al. Efficacy and safety of esketamine nasal spray in patients with treatment-resistant depression who completed a second induction period: analysis of the ongoing SUSTAIN-3 study. CNS Drugs. 2023; 37: 715-723.

[28] Rothärmel M, Benosman C, El-Hage W, et al. Efficacy and safety of intranasal esketamine in patients with treatment-resistant depression and comorbid chronic post-traumatic stress disorder: open-label single-arm pilot study. Front Psychiatry. 2022; 13:865466.

[29] Griva K, Lim PXH, Chan FHF, et al. HED-start: a brief positive psychology cluster-randomized controlled trial to improve psychological adjustment in patients new on hemodialysis. Ann Behav Med Publ Soc Behav Med. 2024; 58: 809-819.

[30] Tan C, Wang J, Cao G, et al. Reliability and validity of the Chinese version of the athens insomnia scale for non-clinical application in chinese athletes. Front Psychol. 2023; 14:1183919.

[31] Ichiba T, Takakuwa H, Suzuki M. The effect of regular periocular skin warming before bedtime on sleep and anxiety: a randomised clinical trial. J Sleep Res. 2025; 34:e14350.

[32] Zhu N, Tong J, Pei Y, et al. Factors associated with objective and subjective cognitive impairment in Chinese patients with acute major depressive disorder. BMC Psychiatry. 2023; 23: 348.

[33] Abdel Hamid AAL, Nasreldin M, Gohar SM, et al. Sexual and religious obsessions in relation to suicidal ideation in bipolar disorder. Suicide Life Threat Behav. 2019; 49: 1552-1559.

[34] Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry J Ment Sci. 1978; 133: 429-435.

[35] Chan DW, Lai B. Assessing psychopathology in Chinese psychiatric patients in hong kong using the brief psychiatric rating scale. Acta Psychiatr Scand. 1993; 87: 37-44.

[36] Lesh TA, Bergé D, Smucny J, et al. Elevated extracellular free water in the brain predicts clinical improvement in first-episode psychosis. Biol Psychiatry Cogn Neurosci Neuroimaging. 2025; 10: 111-119.

[37] Thompson PA, Buckley PF, Meltzer HY. The brief psychiatric rating scale: effect of scaling system on clinical response assessment. J Clin Psychopharmacol. 1994; 14: 344-346.

[38] Zheng W, Zhou Y-L, Liu W-J, et al. Investigation of medical effect of multiple ketamine infusions on patients with major depressive disorder. J Psychopharmacol Oxf Engl. 2019; 33: 494-501.

[39] Bremner JD, Williamson D, Vaccarino V. Psychometric properties of the 23-item clinician administered dissociative states scale (CADSS) in a psychological trauma population. J Affect Disord. 2024; 364: 249-258.

[40] Kishimoto T, Chawla JM, Hagi K, et al. Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med. 2016; 46: 1459-1472.

[41] Zhou Y, Sun W, Zhang G, et al. Ketamine alleviates depressive symptoms in patients undergoing intracranial tumor resection: a randomized controlled trial. Anesth Analg. 2021; 133: 1588-1597.

[42] Li L, Vlisides PE. Ketamine: 50 years of modulating the mind. Front Hum Neurosci. 2016; 10: 612.

[43] Wang S, Hao W, Fan H, et al. Effectiveness and safety of esketamine in laparoscopic surgery patients: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2025; 16:1663348.

[44] Zanos P, Moaddel R, Morris PJ, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016; 533: 481-486.

[45] Luckenbaugh DA, Niciu MJ, Ionescu DF, et al. Do the dissociative side effects of ketamine mediate its antidepressant effects?. J Affect Disord. 2014; 159: 56-61.

[46] Johnston JN, Kadriu B, Kraus C, et al. Ketamine in neuropsychiatric disorders: an update. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2024; 49: 23-40.

[47] Huang C, Hu L, Liu W, et al. Efficacy and safety of esketamine on major depression, postpartum depression and perioperative depression: a systematic review and meta-analysis. Mol Psychiatry. 2026; 31: 545-558.

[48] Niu G, Zheng X, Deng B, et al. The effects of prophylactic use of esketamine on postoperative depression and quality of life: a meta-analysis. Minerva Anestesiol. 2024; 90: 321-329.

[49] Theresa L, Ashleigh S, Josephine F, et al. Randomized trial of ketamine masked by surgical anesthesia in patients with depression. Nat Ment Health. 2023; 1: 876-886.

[50] Liu Q-R, Zong Q-K, Ding L-L, et al. Effects of perioperative use of esketamine on postpartum depression risk in patients undergoing cesarean section: a randomized controlled trial. J Affect Disord. 2023; 339: 815-822.

[51] Wang S, Deng C-M, Zeng Y, et al. Efficacy of a single low dose of esketamine after childbirth for mothers with symptoms of prenatal depression: randomised clinical trial. BMJ. 2024; 385:e078218.

[52] Chen H, Ding X, Xiang G, et al. Analysis of the efficacy of subclinical doses of esketamine in combination with propofol in non-intubated general anesthesia procedures—a systematic review and meta-analysis. BMC Anesthesiol. 2023; 23: 245.

RIGHTS & PERMISSIONS

2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.